Pain Management Devices Market - Global Forecast To 2029
商品番号 : SMB-8683
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年10月 |
| ページ数 | 298 |
| 図表数 | 358 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global pain management devices market is projected to reach USD 5,835.8 million by 2029 from USD 3,768.6 million in 2024, at a CAGR of 9.1% during the forecast period.
世界の疼痛管理デバイス市場は、2024年の37億6,860万米ドルから2029年までに58億3,580万米ドルに達すると予測されており、予測期間中のCAGRは9.1%です。
The rapid growth in the geriatric population globally and the significant rise in the patients with chronic pain conditions are expected to boost the demand for pain management devices market. Moreover, gradual rise in utilization of pain management devices due to improved awareness among patients is likely to support the market growth. Advancements in pain management devices technology, new product launches, favourable reimbursement and government policies, investments in healthcare infrastructure, and initiatives to enhance the accessibility and affordability of pain management devices is anticipated to fuel the market growth.
“The Neurostimulation devices segment of pain management devices market to grow with the highest CAGR during the forecast period.”
Based on the pain management devices market, the Neurostimulation devices pain management devices segment is anticipated to grow at significant rate during forecast period. The demand for neurostimulation devices in the pain management market is increasing due to their effectiveness in treating chronic pain, their minimally invasive nature, and advancements in technology that enhance their functionality and patient comfort .These factors are fostering the growth of neurostimulation devices at higher pace.
“The neuropathic pain segment of application segment to capture the largest market share of pain management devices market.”
Based on application, the pain management devices market is segmented into neuropathic pain, musculoskeletal pain, cancer pain, facial & migraine , and other applications. The neuropathic segment is to capture the largest share and the higher CAGR during the forecast period. Owing to high prevalence of neuropathic pain across the globe, presence of substantial clinical evidence in the favor of high efficacy of pain management devices in neuropathic pain treatment, development of novel devices, the rising geriatric population is at high risk of neuropathic pain due to the increased incidence of neuropathic pain associated with many age-related diseases, side effects of drugs used to treat neuropathic pain, and availability of favorable reimbursement are boosting the adoption of pain management devices for neuropathic pain conditions.
“North America accounted for the largest share of the pain management devices market by region.”
The global pain management devices market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for pain management devices, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.
The largest share of North America is attributed to the high disease burden of chronic disease and pain conditions contributing to a larger pool of patients requiring pain management devices products. The presence of numerous potential market giants and favorable reimbursement policy in the region is likely to promote the growth of pain management devices market in North America.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–60%, Tier 2–30%, and Tier 3– 10%
- By Designation: Directors–50%, Managers–30% and Others–20%
- By Region: North America–45%, Europe–15%, Asia Pacific–25% and RoW–15%
The major players operating in the pain management devices market market are Medtronic (Ireland), Boston Scientific Corporation(US), Abbott Laboratories (US), Stryker (US), Nevro Corp. (US), Becton, Dickinson and Company (US), Baxter (US), B. Braun SE (Germany), Omron Corporation (Japan), Avanos Medical, Inc. (US), Teleflex Incorporated (US),ICU Medical, Inc. (US), Nipro (Japan), Moog Inc. (US), Atricure, Inc. (US), Micrel Medical Devices SA (Greece), Zynex, Inc.(US), and Enovis Corporation (US).
Research Coverage
This report studies the pain management devices market based on type, application, mode of purchase, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
Analysis of Key divers (increasing prevalence of chronic pain conditions, rising demand of pain management devices in home care settings, , new product launches & approvals, favourable reimbursement scenario and government initiatives), restraints (high procedural cost, product recalls), Opportunities (emerging markets, expanding base of pain management clinics/centers ) , Challenge (stringent regulatory requirement, use of pain medication as first-line treatment for pain management)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pain management devices market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pain management devices market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS 28
1.3 STUDY SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED 30
1.3.3 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
2.1.2.1 Key data from primary sources 35
2.1.2.2 Insights from industry experts 36
2.1.2.3 Breakdown of primary interviews 36
2.1.2.4 Supply-side and demand-side participants 37
2.2 MARKET SIZE ESTIMATION 37
2.2.1 BOTTOM-UP APPROACH 37
2.2.2 TOP-DOWN APPROACH 40
2.3 DATA TRIANGULATION 41
2.4 RESEARCH ASSUMPTIONS 42
2.5 RESEARCH LIMITATIONS 42
2.6 RISK ASSESSMENT 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 48
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PAIN MANAGEMENT DEVICES MARKET 48
4.2 ASIA PACIFIC PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION AND COUNTRY 49
4.3 PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Surge in demand for at-home pain management devices 52
5.2.1.2 Increase in surgical procedures 52
5.2.1.3 Prevalence of chronic pain conditions 53
5.2.1.4 Favorable reimbursement policies for spinal cord stimulation devices 53
5.2.1.5 Growing launches and regulatory approvals for advanced
pain management devices 54
5.2.2 RESTRAINTS 54
5.2.2.1 Rise in product recalls 54
5.2.2.2 High procedural and purchase cost of pain management devices 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Untapped growth potential in emerging economies 55
5.2.3.2 Expansion of pain management clinics 56
5.2.4 CHALLENGES 56
5.2.4.1 Use of pain medication as first line of treatment 56
5.2.4.2 Stringent regulatory norms for FDA approval 56
5.3 TECHNOLOGY ANALYSIS 57
5.3.1 KEY TECHNOLOGIES 57
5.3.1.1 Wearable devices 57
5.3.1.2 Implantable pumps 57
5.3.2 COMPLEMENTARY TECHNOLOGIES 58
5.3.2.1 Virtual reality 58
5.3.2.2 Digital therapeutics 58
5.3.3 ADJACENT TECHNOLOGIES 58
5.3.3.1 Robotics 58
5.4 INDUSTRY TRENDS 58
5.4.1 ELECTROTHERAPY DEVICES 58
5.4.2 RECHARGEABLE SPINAL CORD STIMULATORS 59
5.5 SUPPLY CHAIN ANALYSIS 59
5.6 TRADE ANALYSIS 61
5.7 PORTER’S FIVE FORCES ANALYSIS 62
5.7.1 THREAT FROM NEW ENTRANTS 63
5.7.2 THREAT FROM SUBSTITUTES 64
5.7.3 BARGAINING POWER OF SUPPLIERS 64
5.7.4 BARGAINING POWER OF BUYERS 64
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.8 REGULATORY LANDSCAPE 65
5.8.1 NORTH AMERICA 66
5.8.1.1 US 66
5.8.1.2 Canada 67
5.8.2 EUROPE 68
5.8.3 ASIA PACIFIC 71
5.8.3.1 Japan 71
5.8.3.2 China 71
5.8.3.3 India 72
5.8.4 LATIN AMERICA 73
5.8.4.1 Brazil 73
5.8.4.2 Mexico 75
5.8.5 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
5.9 PATENT ANALYSIS 80
5.10 PRICING ANALYSIS 82
5.11 KEY CONFERENCES AND EVENTS, 2024–2025 83
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 84
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 84
5.12.2 BUYING CRITERIA 85
5.13 ECOSYSTEM ANALYSIS 86
5.14 CASE STUDY ANALYSIS 88
5.15 REIMBURSEMENT ANALYSIS 89
5.16 UNMET NEEDS IN PAIN MANAGEMENT DEVICES MARKET 90
5.17 VALUE CHAIN ANALYSIS 91
5.18 END USER EXPECTATIONS IN PAIN MANAGEMENT DEVICES MARKET 92
5.19 IMPACT OF AI/GEN AI IN PAIN MANAGEMENT DEVICES MARKET 93
5.20 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
5.21 INVESTMENT AND FUNDING SCENARIO 94
6 PAIN MANAGEMENT DEVICES MARKET, BY TYPE 95
6.1 INTRODUCTION 96
6.2 NEUROSTIMULATION DEVICES 96
6.2.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS 99
6.2.1.1 Surge in demand for non-invasive therapy to drive market 99
6.2.2 SPINAL CORD STIMULATORS 101
6.2.2.1 Extensive use of SCS for pain treatment to drive market 101
6.2.3 OTHERS 103
6.3 INFUSION PUMPS 105
6.3.1 INTRATHECAL INFUSION PUMPS 107
6.3.1.1 Increasing incidences of chronic pain to drive market 107
6.3.2 EXTERNAL INFUSION PUMPS 109
6.3.2.1 Availability of reimbursement to drive market 109
6.4 ABLATION DEVICES 111
6.4.1 RADIOFREQUENCY ABLATION DEVICES 113
6.4.1.1 Low cost of RF ablation procedures to drive market 113
6.4.2 CRYOABLATION ABLATION DEVICES 115
6.4.2.1 Successful clinical trials to drive market 115
6.4.3 ULTRASOUND ABLATION DEVICES 116
6.4.3.1 Efficacy in targeted pain management to drive market 116
6.4.4 OTHERS 118
7 PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION 119
7.1 INTRODUCTION 120
7.2 NEUROPATHIC PAIN 120
7.2.1 HIGH EFFICACY OF PAIN MANAGEMENT DEVICES IN NEUROPATHIC
PAIN TREATMENT TO DRIVE MARKET 120
7.3 MUSCULOSKELETAL PAIN 122
7.3.1 SURGE IN AGING POPULATION TO DRIVE MARKET 122
7.4 CANCER PAIN 124
7.4.1 PREVALENCE OF CANCER TO DRIVE MARKET 124
7.5 FACIAL PAIN & MIGRAINE 126
7.5.1 INTRODUCTION OF NOVEL PAIN MANAGEMENT DEVICES TO DRIVE MARKET 126
7.6 OTHER APPLICATIONS 127
8 PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE 129
8.1 INTRODUCTION 130
8.2 PRESCRIPTION-BASED 130
8.2.1 INCREASING INCIDENCES OF MEDICAL DISORDERS TO DRIVE MARKET 130
8.3 OVER-THE-COUNTER 132
8.3.1 ACCESSIBILITY OF OTC PAIN MANAGEMENT DEVICES TO DRIVE MARKET 132
9 PAIN MANAGEMENT DEVICES MARKET, BY END USER 134
9.1 INTRODUCTION 135
9.2 HOSPITALS & CLINICS 135
9.3 PHYSIOTHERAPY CENTERS 137
9.3.1 RISE OF SPORTS INJURIES AND MUSCULOSKELETAL DISORDERS
TO DRIVE MARKET 137
9.4 HOME CARE SETTINGS 139
9.4.1 HIGH COST OF HOSPITALIZATION TO DRIVE MARKET 139
9.5 OTHER END USERS 141
10 PAIN MANAGEMENT DEVICES MARKET, BY REGION 142
10.1 INTRODUCTION 143
10.2 NORTH AMERICA 143
10.2.1 MACROECONOMIC OUTLOOK 147
10.2.2 US 148
10.2.2.1 Favorable reimbursement policies to drive market 148
10.2.3 CANADA 151
10.2.3.1 Increasing incidences of chronic pain to drive market 151
10.3 EUROPE 154
10.3.1 MACROECONOMIC OUTLOOK 157
10.3.2 GERMANY 158
10.3.2.1 Robust healthcare infrastructure to drive market 158
10.3.3 FRANCE 161
10.3.3.1 Government initiatives for lowering healthcare costs to drive market 161
10.3.4 UK 164
10.3.4.1 Shift toward home care settings to drive market 164
10.3.5 ITALY 167
10.3.5.1 Growing healthcare investments to drive market 167
10.3.6 SPAIN 169
10.3.6.1 Surge in new cancer cases to drive market 169
10.3.7 REST OF EUROPE 172
10.4 ASIA PACIFIC 175
10.4.1 MACROECONOMIC OUTLOOK 179
10.4.2 JAPAN 181
10.4.2.1 Large geriatric population to drive market 181
10.4.3 CHINA 183
10.4.3.1 Growing investments in healthcare infrastructure development to drive market 183
10.4.4 INDIA 186
10.4.4.1 High prevalence of lifestyle diseases to drive market 186
10.4.5 AUSTRALIA 189
10.4.5.1 Initiatives promoting development of novel pain management devices to drive market 189
10.4.6 SOUTH KOREA 192
10.4.6.1 Growing demand for effective treatment options to drive market 192
10.4.7 REST OF ASIA PACIFIC 194
10.5 LATIN AMERICA 197
10.5.1 MACROECONOMIC OUTLOOK 200
10.5.2 BRAZIL 201
10.5.2.1 Private and government sector awareness programs to drive market 201
10.5.3 MEXICO 204
10.5.3.1 Domestic health coverage schemes to drive market 204
10.5.4 REST OF LATIN AMERICA 206
10.6 MIDDLE EAST & AFRICA 209
10.6.1 MACROECONOMIC OUTLOOK 212
10.6.2 GCC COUNTRIES 213
10.6.2.1 High healthcare spending capacity to drive market 213
10.6.3 REST OF MIDDLE EAST & AFRICA 216
11 COMPETITIVE LANDSCAPE 219
11.1 INTRODUCTION 219
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024 219
11.3 REVENUE ANALYSIS, 2021–2023 220
11.4 MARKET SHARE ANALYSIS, 2023 221
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 222
11.5.1 STARS 223
11.5.2 EMERGING LEADERS 223
11.5.3 PERVASIVE PLAYERS 223
11.5.4 PARTICIPANTS 223
11.5.5 COMPANY FOOTPRINT 224
11.5.5.1 Company footprint 225
11.5.5.2 Type footprint 226
11.5.5.3 Region footprint 227
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 228
11.6.1 PROGRESSIVE COMPANIES 228
11.6.2 RESPONSIVE COMPANIES 228
11.6.3 DYNAMIC COMPANIES 228
11.6.4 STARTING BLOCKS 228
11.6.5 COMPETITIVE BENCHMARKING 230
11.7 BRAND/PRODUCT COMPARISON 231
11.8 R&D ASSESSMENT 232
11.9 COMPANY VALUATION AND FINANCIAL METRICS 232
11.10 COMPETITIVE SCENARIO 233
11.10.1 PRODUCT APPROVALS/LAUNCHES 233
11.10.2 DEALS 234
11.10.3 EXPANSIONS 235
11.10.4 OTHERS 235
12 COMPANY PROFILES 236
12.1 KEY PLAYERS 236
12.1.1 MEDTRONIC 236
12.1.1.1 Business overview 236
12.1.1.2 Products offered 237
12.1.1.3 Recent developments 238
12.1.1.3.1 Product approvals/launches 238
12.1.1.4 MnM view 239
12.1.1.4.1 Key strengths 239
12.1.1.4.2 Strategic choices 239
12.1.1.4.3 Weaknesses and competitive threats 239
12.1.2 BOSTON SCIENTIFIC CORPORATION 240
12.1.2.1 Business overview 240
12.1.2.2 Products offered 241
12.1.2.3 Recent developments 242
12.1.2.3.1 Deals 242
12.1.2.4 MnM view 242
12.1.2.4.1 Key strengths 242
12.1.2.4.2 Strategic choices 242
12.1.2.4.3 Weaknesses and competitive threats 242
12.1.3 ABBOTT LABORATORIES 243
12.1.3.1 Business overview 243
12.1.3.2 Product offered 244
12.1.3.3 Recent developments 245
12.1.3.3.1 Product approvals/launches 245
12.1.3.4 MnM view 245
12.1.3.4.1 Key strengths 245
12.1.3.4.2 Strategic choices 245
12.1.3.4.3 Weaknesses and competitive threats 246
12.1.4 NEVRO CORP. 247
12.1.4.1 Business overview 247
12.1.4.2 Products offered 248
12.1.4.3 Recent developments 248
12.1.4.3.1 Product approvals/launches 248
12.1.4.3.2 Deals 248
12.1.4.4 MnM view 249
12.1.4.4.1 Key strengths 249
12.1.4.4.2 Strategic choices 249
12.1.4.4.3 Weaknesses and competitive threats 249
12.1.5 BECTON, DICKINSON AND COMPANY 250
12.1.5.1 Business overview 250
12.1.5.2 Products offered 251
12.1.5.3 Recent developments 252
12.1.5.3.1 Others 252
12.1.5.4 MnM view 252
12.1.5.4.1 Right to win 252
12.1.5.4.2 Strategic choices 252
12.1.5.4.3 Weaknesses and competitive threats 252
12.1.6 STRYKER 253
12.1.6.1 Business overview 253
12.1.6.2 Products offered 254
12.1.6.3 Recent developments 255
12.1.6.3.1 Expansions 255
12.1.7 B. BRAUN SE 256
12.1.7.1 Business overview 256
12.1.7.2 Products offered 257
12.1.7.3 Recent developments 259
12.1.7.3.1 Deals 259
12.1.7.3.2 Others 259
12.1.8 BAXTER 260
12.1.8.1 Business overview 260
12.1.8.2 Products offered 262
12.1.9 OMRON CORPORATION 263
12.1.9.1 Business overview 263
12.1.9.2 Products offered 264
12.1.10 AVANOS MEDICAL, INC. 265
12.1.10.1 Business overview 265
12.1.10.2 Products offered 266
12.1.10.2.1 Deals 266
12.1.11 TELEFLEX INCORPORATED 267
12.1.11.1 Business overview 267
12.1.11.2 Products offered 268
12.1.12 ICU MEDICAL, INC. 269
12.1.12.1 Business overview 269
12.1.12.2 Products offered 270
12.1.12.3 Recent developments 271
12.1.12.3.1 Deals 271
12.1.13 NIPRO 272
12.1.13.1 Business overview 272
12.1.13.2 Products offered 274
12.1.13.3 Recent developments 274
12.1.13.3.1 Expansions 274
12.1.14 MOOG INC. 275
12.1.14.1 Business overview 275
12.1.14.2 Products offered 277
12.1.15 ATRICURE, INC. 278
12.1.15.1 Business overview 278
12.1.15.2 Products offered 279
12.1.15.3 Recent developments 279
12.1.15.3.1 Product approvals/launches 279
12.1.16 MICREL MEDICAL DEVICES SA 280
12.1.16.1 Business overview 280
12.1.16.2 Products offered 281
12.1.17 ZYNEX, INC. 282
12.1.17.1 Business overview 282
12.1.17.2 Products offered 283
12.1.18 ENOVIS CORPORATION 284
12.1.18.1 Business overview 284
12.1.18.2 Products offered 285
12.2 OTHER PLAYERS 286
12.2.1 EPIC MEDICAL 286
12.2.2 SOTERIX MEDICAL INC. 286
12.2.3 GIMER MEDICAL 287
12.2.4 NEURONANO AB 287
12.2.5 ICECURE MEDICAL 288
12.2.6 BIOWAVE 288
12.2.7 THERANICA BIO-ELECTRONICS LTD. 289
13 APPENDIX 290
13.1 DISCUSSION GUIDE 290
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 294
13.3 CUSTOMIZATION OPTIONS 296
13.4 RELATED REPORTS 296
13.5 AUTHOR DETAILS 297
LIST OF TABLES
TABLE 1 STANDARD EXCHANGE RATES 30
TABLE 2 IMPORT DATA FOR HS CODE 901890, BY COUNTRY,
2019–2023 (USD THOUSAND) 61
TABLE 3 EXPORT DATA FOR HS CODE 901890, BY COUNTRY,
2019–2023 (USD THOUSAND) 62
TABLE 4 IMPACT OF PORTER’S FIVE FORCES 62
TABLE 5 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING
PAIN MANAGEMENT DEVICES 65
TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION 66
TABLE 7 US: CLASSIFICATION OF MEDICAL DEVICES 66
TABLE 8 CANADA: CLASSIFICATION OF MEDICAL DEVICES 67
TABLE 9 JAPAN: CLASSIFICATION OF MEDICAL DEVICES 71
TABLE 10 CHINA: CLASSIFICATION OF MEDICAL DEVICES 72
TABLE 11 BRAZIL: CLASSIFICATION OF MEDICAL DEVICES 74
TABLE 12 MEXICO: CLASSIFICATION OF MEDICAL DEVICES 76
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 18 PATENT ANALYSIS, 2023–2024 81
TABLE 19 INDICATIVE PRICING OF PAIN MANAGEMENT DEVICES, BY REGION, 2023 (USD) 83
TABLE 20 KEY CONFERENCES AND EVENTS, 2024–2025 83
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 85
TABLE 22 KEY BUYING CRITERIA, BY TYPE 85
TABLE 23 ROLE OF COMPANIES IN ECOSYSTEM 87
TABLE 24 CELIAC PLEXUS CRYO-NEUROLYSIS FOR PALLIATIVE PAIN MANAGEMENT IN PANCREATIC CANCER 88
TABLE 25 GET READY REMOTE PATIENT MANAGEMENT SOLUTION FOR TIMELY CHRONIC PAIN TREATMENT OF 88
TABLE 26 MEDICARE CODING AND NATIONAL PAYMENT RATES FOR RADIOFREQUENCY ABLATION (SACROILIAC JOINT) PROCEDURES 89
TABLE 27 MEDICARE CODING AND NATIONAL PHYSICIAN PAYMENT RATES FOR SPINAL CORD STIMULATION PROCEDURES 89
TABLE 28 PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 96
TABLE 29 NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 97
TABLE 30 NEUROSTIMULATION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 31 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 32 SPINAL CORD STIMULATORS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 33 OTHER NEUROSTIMULATION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 104
TABLE 34 INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 105
TABLE 35 INFUSION PUMPS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 36 INTRATHECAL INFUSION PUMPS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 108
TABLE 37 EXTERNAL INFUSION PUMPS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 38 ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 111
TABLE 39 ABLATION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 40 RF ABLATION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 41 CRYOABLATION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 42 ULTRASOUND DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 43 OTHER ABLATION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 44 PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 120
TABLE 45 NEUROPATHIC PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 121
TABLE 46 MUSCULOSKELETAL PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 47 CANCER PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 48 FACIAL PAIN & MIGRAINE MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 127
TABLE 49 OTHER PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 128
TABLE 50 PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 130
TABLE 51 PRESCRIPTION-BASED PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 52 OVER-THE-COUNTER PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 53 PAIN MANAGEMENT DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 135
TABLE 54 PAIN MANAGEMENT DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 55 PAIN MANAGEMENT DEVICES MARKET FOR PHYSIOTHERAPY CLINICS,
BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 56 PAIN MANAGEMENT DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 57 PAIN MANAGEMENT DEVICES MARKET FOR OTHERS, BY COUNTRY,
2022–2029 (USD MILLION) 141
TABLE 58 PAIN MANAGEMENT DEVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 59 NORTH AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 144
TABLE 60 NORTH AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 145
TABLE 61 NORTH AMERICA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 145
TABLE 62 NORTH AMERICA: INFUSION PUMPS MARKET, BY TYPE,
2022–2029 (USD MILLION) 145
TABLE 63 NORTH AMERICA: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 146
TABLE 64 NORTH AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 146
TABLE 65 NORTH AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 146
TABLE 66 NORTH AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 147
TABLE 67 NORTH AMERICA: KEY MACRO INDICATORS 148
TABLE 68 US: PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 69 US: NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 70 US: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 71 US: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 72 US: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 150
TABLE 73 US: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 150
TABLE 74 US: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 151
TABLE 75 CANADA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 152
TABLE 76 CANADA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 152
TABLE 77 CANADA: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 152
TABLE 78 CANADA: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 79 CANADA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 153
TABLE 80 CANADA: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 153
TABLE 81 CANADA: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 154
TABLE 82 EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 155
TABLE 83 EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 155
TABLE 84 EUROPE: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 155
TABLE 85 EUROPE: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 86 EUROPE: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 87 EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 156
TABLE 88 EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 157
TABLE 89 EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 157
TABLE 90 EUROPE: KEY MACRO INDICATORS 158
TABLE 91 GERMANY: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 159
TABLE 92 GERMANY: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 159
TABLE 93 GERMANY: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 159
TABLE 94 GERMANY: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
TABLE 95 GERMANY: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 160
TABLE 96 GERMANY: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 160
TABLE 97 GERMANY: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 161
TABLE 98 FRANCE: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 161
TABLE 99 FRANCE: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 162
TABLE 100 FRANCE: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 101 FRANCE: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 102 FRANCE: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 163
TABLE 103 FRANCE: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 163
TABLE 104 FRANCE: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 163
TABLE 105 UK: PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 106 UK: NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 107 UK: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 108 UK: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 109 UK: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 166
TABLE 110 UK: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 166
TABLE 111 UK: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 166
TABLE 112 ITALY: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 167
TABLE 113 ITALY: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 167
TABLE 114 ITALY: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 115 ITALY: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 116 ITALY: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 168
TABLE 117 ITALY: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 169
TABLE 118 ITALY: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 169
TABLE 119 SPAIN: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 170
TABLE 120 SPAIN: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 170
TABLE 121 SPAIN: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 122 SPAIN: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 123 SPAIN: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 171
TABLE 124 SPAIN: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 171
TABLE 125 SPAIN: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 172
TABLE 126 REST OF EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 173
TABLE 127 REST OF EUROPE: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 173
TABLE 128 REST OF EUROPE: INFUSION PUMPS MARKET, BY TYPE,
2022–2029 (USD MILLION) 173
TABLE 129 REST OF EUROPE: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 174
TABLE 130 REST OF EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 174
TABLE 131 REST OF EUROPE: PAIN MANAGEMENT DEVICES MARKET,
BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 174
TABLE 132 REST OF EUROPE: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 175
TABLE 133 ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 177
TABLE 134 ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 177
TABLE 135 ASIA PACIFIC: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 177
TABLE 136 ASIA PACIFIC: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 137 ASIA PACIFIC: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 138 ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 178
TABLE 139 ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 179
TABLE 140 ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 179
TABLE 141 ASIA PACIFIC: KEY MACRO INDICATORS 180
TABLE 142 JAPAN: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 181
TABLE 143 JAPAN: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 181
TABLE 144 JAPAN: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 145 JAPAN: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 146 JAPAN: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 182
TABLE 147 JAPAN: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 183
TABLE 148 JAPAN: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 183
TABLE 149 CHINA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 184
TABLE 150 CHINA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 184
TABLE 151 CHINA: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 152 CHINA: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 153 CHINA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 185
TABLE 154 CHINA: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 185
TABLE 155 CHINA: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 186
TABLE 156 INDIA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 186
TABLE 157 INDIA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 187
TABLE 158 INDIA: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 159 INDIA: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 160 INDIA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 188
TABLE 161 INDIA: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 188
TABLE 162 INDIA: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 188
TABLE 163 AUSTRALIA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 189
TABLE 164 AUSTRALIA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 190
TABLE 165 AUSTRALIA: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 166 AUSTRALIA: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 167 AUSTRALIA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 191
TABLE 168 AUSTRALIA: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 191
TABLE 169 AUSTRALIA: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 191
TABLE 170 SOUTH KOREA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 192
TABLE 171 SOUTH KOREA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 192
TABLE 172 SOUTH KOREA: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 173 SOUTH KOREA: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 174 SOUTH KOREA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 193
TABLE 175 SOUTH KOREA: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 194
TABLE 176 SOUTH KOREA: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 194
TABLE 177 REST OF ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 178 REST OF ASIA PACIFIC: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 179 REST OF ASIA PACIFIC: INFUSION PUMPS MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 180 REST OF ASIA PACIFIC: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 196
TABLE 181 REST OF ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 196
TABLE 182 REST OF ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET,
BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 196
TABLE 183 REST OF ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 197
TABLE 184 LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 198
TABLE 185 LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 198
TABLE 186 LATIN AMERICA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 198
TABLE 187 LATIN AMERICA: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 188 LATIN AMERICA: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 189 LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 199
TABLE 190 LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 200
TABLE 191 LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 200
TABLE 192 LATIN AMERICA: KEY MACRO INDICATORS 201
TABLE 193 BRAZIL: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 201
TABLE 194 BRAZIL: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 202
TABLE 195 BRAZIL: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 196 BRAZIL: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 197 BRAZIL: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 203
TABLE 198 BRAZIL: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 203
TABLE 199 BRAZIL: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 203
TABLE 200 MEXICO: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 204
TABLE 201 MEXICO: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 204
TABLE 202 MEXICO: INFUSION PUMPS MARKET, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 203 MEXICO: ABLATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 204 MEXICO: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 205
TABLE 205 MEXICO: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2022–2029 (USD MILLION) 205
TABLE 206 MEXICO: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 206
TABLE 207 REST OF LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 206
TABLE 208 REST OF LATIN AMERICA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 209 REST OF LATIN AMERICA: INFUSION PUMPS MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 210 REST OF LATIN AMERICA: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 211 REST OF LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 208
TABLE 212 REST OF LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET,
BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 208
TABLE 213 REST OF LATIN AMERICA: PAIN MANAGEMENT DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 208
TABLE 214 MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 209
TABLE 215 MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 209
TABLE 216 MIDDLE EAST & AFRICA: NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 210
TABLE 217 MIDDLE EAST & AFRICA: INFUSION PUMPS MARKET, BY TYPE,
2022–2029 (USD MILLION) 210
TABLE 218 MIDDLE EAST & AFRICA: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 210
TABLE 219 MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 211
TABLE 220 MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET,
BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 211
TABLE 221 MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 211
TABLE 222 MIDDLE EAST & AFRICA: KEY MACRO INDICATORS 212
TABLE 223 GCC COUNTRIES: PAIN MANAGEMENT DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 213
TABLE 224 GCC COUNTRIES NEUROSTIMULATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 214
TABLE 225 GCC COUNTRIES: INFUSION PUMPS MARKET, BY TYPE,
2022–2029 (USD MILLION) 214
TABLE 226 GCC COUNTRIES: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 214
TABLE 227 GCC COUNTRIES: PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 215
TABLE 228 GCC COUNTRIES: PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 215
TABLE 229 GCC COUNTRIES: PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 215
TABLE 230 REST OF MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 231 REST OF MIDDLE EAST & AFRICA: NEUROSTIMULATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 232 REST OF MIDDLE EAST & AFRICA: INFUSION PUMPS MARKET, BY TYPE,
2022–2029 (USD MILLION) 217
TABLE 233 REST OF MIDDLE EAST & AFRICA: ABLATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 217
TABLE 234 REST OF MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 217
TABLE 235 REST OF MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET,
BY MODE OF PURCHASE, 2022–2029 (USD MILLION) 218
TABLE 236 REST OF MIDDLE EAST & AFRICA: PAIN MANAGEMENT DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 218
TABLE 237 PAIN MANAGEMENT DEVICES MARKET: DEGREE OF COMPETITION 221
TABLE 238 TYPE FOOTPRINT 226
TABLE 239 REGION FOOTPRINT 227
TABLE 240 LIST OF START-UPS/SMES 230
TABLE 241 COMPETITIVE BENCHMARKING OF START-UPS/SMES 230
TABLE 242 PAIN MANAGEMENT DEVICES MARKET: PRODUCT APPROVALS/LAUNCHES, JANUARY 2021–SEPTEMBER 2024 233
TABLE 243 PAIN MANAGEMENT DEVICES MARKET: DEALS, JANUARY 2021–SEPTEMBER 2024 234
TABLE 244 PAIN MANAGEMENT DEVICES MARKET: EXPANSIONS,
JANUARY 2021–SEPTEMBER 2024 235
TABLE 245 PAIN MANAGEMENT DEVICES MARKET: OTHERS,
JANUARY 2021–SEPTEMBER 2024 235
TABLE 246 MEDTRONIC: COMPANY OVERVIEW 236
TABLE 247 MEDTRONIC: PRODUCTS OFFERED 237
TABLE 248 MEDTRONIC: PRODUCT APPROVALS/LAUNCHES 238
TABLE 249 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 240
TABLE 250 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 241
TABLE 251 BOSTON SCIENTIFIC CORPORATION: DEALS 242
TABLE 252 ABBOTT LABORATORIES: COMPANY OVERVIEW 243
TABLE 253 ABBOTT LABORATORIES: PRODUCTS OFFERED 244
TABLE 254 ABBOTT LABORATORIES: PRODUCT LUNCHES/APPROVALS 245
TABLE 255 NEVRO CORP.: COMPANY OVERVIEW 247
TABLE 256 NEVRO CORP: PRODUCTS OFFERED 248
TABLE 257 NEVRO CORP.: PRODUCT APPROVALS/LAUNCHES 248
TABLE 258 NEVRO CORP.: DEALS, JANUARY 2021− SEPTEMBER 2024 248
TABLE 259 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 250
TABLE 260 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 251
TABLE 261 BECTON, DICKINSON AND COMPANY: OTHERS 252
TABLE 262 STRYKER: COMPANY OVERVIEW 253
TABLE 263 STRYKER: PRODUCTS OFFERED 254
TABLE 264 STRYKER: EXPANSIONS 255
TABLE 265 B. BRAUN SE: COMPANY OVERVIEW 256
TABLE 266 B. BRAUN SE: PRODUCTS OFFERED 257
TABLE 267 B. BRAUN SE: DEALS 259
TABLE 268 B. BRAUN SE: OTHERS 259
TABLE 269 BAXTER: COMPANY OVERVIEW 260
TABLE 270 BAXTER: PRODUCTS OFFERED 262
TABLE 271 OMRON CORPORATION: COMPANY OVERVIEW 263
TABLE 272 OMRON CORPORATION: PRODUCTS OFFERED 264
TABLE 273 AVANOS MEDICAL, INC.: COMPANY OVERVIEW 265
TABLE 274 AVANOS MEDICAL, INC.: PRODUCTS OFFERED 266
TABLE 275 AVANOS MEDICAL, INC.: DEALS 266
TABLE 276 TELEFLEX INCORPORATED: COMPANY OVERVIEW 267
TABLE 277 TELEFLEX INCORPORATED: PRODUCTS OFFERED 268
TABLE 278 ICU MEDICAL, INC.:COMPANY OVERVIEW 269
TABLE 279 ICU MEDICAL: PRODUCTS OFFERED 270
TABLE 280 ICU MEDICAL: DEALS 271
TABLE 281 NIPRO: COMPANY OVERVIEW 272
TABLE 282 NIPRO: PRODUCTS OFFERED 274
TABLE 283 NIPRO: EXPANSIONS 274
TABLE 284 MOOG INC.: COMPANY OVERVIEW 275
TABLE 285 MOOG INC.: PRODUCTS OFFERED 277
TABLE 286 ATRICURE, INC.: COMPANY OVERVIEW 278
TABLE 287 ATRICURE, INC.: PRODUCTS OFFERED 279
TABLE 288 ATRICURE, INC.: PRODUCT APPROVALS/ LAUNCHES 279
TABLE 289 MICREL MEDICAL DEVICES SA: COMPANY OVERVIEW 280
TABLE 290 MICREL MEDICAL DEVICES SA: PRODUCTS OFFERED 281
TABLE 291 ZYNEX, INC.: COMPANY OVERVIEW 282
TABLE 292 ZYNEX, INC: PRODUCTS OFFERED 283
TABLE 293 ENOVIS CORPORATION: COMPANY OVERVIEW 284
TABLE 294 ENOVIS CORPORATION: PRODUCTS OFFERED 285
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 32
FIGURE 2 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 37
FIGURE 3 REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC 38
FIGURE 4 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
FIGURE 5 TOP-DOWN APPROACH 40
FIGURE 6 DATA TRIANGULATION 41
FIGURE 7 PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 43
FIGURE 8 NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 44
FIGURE 9 INFUSION PUMPS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 44
FIGURE 10 ABLATION DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 45
FIGURE 11 PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION,
2024 VS. 2029 (USD MILLION) 45
FIGURE 12 PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE,
2024 VS. 2029 (USD MILLION) 46
FIGURE 13 PAIN MANAGEMENT DEVICES MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 46
FIGURE 14 PAIN MANAGEMENT DEVICES MARKET, BY REGION 47
FIGURE 15 GROWING DEMAND FOR LONG-TERM PAIN MANAGEMENT AMONG GERIATRIC POPULATION TO DRIVE MARKET 48
FIGURE 16 NEUROPATHIC PAIN AND CHINA TO BE MAJOR STAKEHOLDERS IN 2023 49
FIGURE 17 CHINA TO FASTEST-GROWING MARKET FOR PAIN MANAGEMENT
DEVICES DURING FORECAST PERIOD 50
FIGURE 18 PAIN MANAGEMENT DEVICES MARKET DYNAMICS 51
FIGURE 19 SUPPLY CHAIN ANALYSIS 60
FIGURE 20 PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 21 PRE-MARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES 67
FIGURE 22 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 68
FIGURE 23 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 70
FIGURE 24 LATIN AMERICA: REGULATORY SCENARIO 73
FIGURE 25 BRAZIL: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 74
FIGURE 26 MEXICO: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 75
FIGURE 27 PATENT ANALYSIS, 2014–2024 80
FIGURE 28 GLOBAL PATENT APPLICATIONS, 2014–2024 81
FIGURE 29 INDICATIVE PRICING OF PAIN MANAGEMENT DEVICES, BY TYPE, 2023 (USD) 82
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 84
FIGURE 31 KEY BUYING CRITERIA, BY TYPE 85
FIGURE 32 ECOSYSTEM ANALYSIS 87
FIGURE 33 VALUE CHAIN ANALYSIS 91
FIGURE 34 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
FIGURE 35 INVESTMENT AND FUNDING SCENARIO, 2019–2023 94
FIGURE 36 NORTH AMERICA: PAIN MANAGEMENT DEVICES MARKET SNAPSHOT 144
FIGURE 37 ASIA PACIFIC: PAIN MANAGEMENT DEVICES MARKET SNAPSHOT 176
FIGURE 38 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024 219
FIGURE 39 REVENUE ANALYSIS OF TOP THREE PLAYERS, 2021–2023 220
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 221
FIGURE 41 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 224
FIGURE 42 COMPANY FOOTPRINT 225
FIGURE 43 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 229
FIGURE 44 BRAND/PRODUCT COMPARISON 231
FIGURE 45 R&D EXPENDITURE OF KEY PLAYERS, 2021–2023 232
FIGURE 46 EV/EBITDA OF KEY VENDORS 232
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR
STOCK BETA OF KEY VENDORS 233
FIGURE 48 MEDTRONIC: COMPANY SNAPSHOT 237
FIGURE 49 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 241
FIGURE 50 ABBOTT LABORATORIES: COMPANY SNAPSHOT 244
FIGURE 51 NEVRO CORP.: COMPANY SNAPSHOT 247
FIGURE 52 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 251
FIGURE 53 STRYKER: COMPANY SNAPSHOT 254
FIGURE 54 B. BRAUN SE: COMPANY SNAPSHOT 257
FIGURE 55 BAXTER: COMPANY SNAPSHOT 261
FIGURE 56 OMRON CORPORATION: COMPANY SNAPSHOT 264
FIGURE 57 AVANOS MEDICAL, INC.: COMPANY SNAPSHOT 265
FIGURE 58 TELEFLEX INCORPORATED: COMPANY SNAPSHOT 268
FIGURE 59 ICU MEDICAL: COMPANY SNAPSHOT 270
FIGURE 60 NIPRO: COMPANY SNAPSHOT 273
FIGURE 61 MOOG INC.: COMPANY SNAPSHOT 276
FIGURE 62 ATRICURE, INC.: COMPANY SNAPSHOT 278
FIGURE 63 ZYNEX, INC.: COMPANY SNAPSHOT 282
FIGURE 64 ENOVIS CORPORATION: COMPANY SNAPSHOT 285
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11